Endüstriler
Showing 31–40 ile ilgili 44 results
-
Bladder Cancer Market in China
StratejiHelix'e göre, the bladder cancer market in China, in terms of volume, is expected to expand at a CAGR of 3.1% analiz dönemi boyunca 2021 ile 2027.
-
Pancreatic Cancer Market in China
According to a statistic by StrategyHelix, the pancreatic cancer market in China, in terms of volume, is expected to expand at a CAGR of 3.3% tahmin dönemi boyunca (2021-2027).
-
Lymphoma Market in China
StratejiHelix'e göre, the lymphoma market in China, in terms of volume, is expected to expand at a CAGR of 2.3% in the next five years.
-
Urothelial Cancer Market in China
According to a statistic by StrategyHelix, the urothelial cancer market in China, in terms of volume, is expected to expand at a CAGR of 3.2% itibaren 2021 başından sonuna kadar 2027.
-
Gastric Cancer Market in China
The gastric cancer market in China was estimated at 470 bin adet 2020 and is anticipated to reach 579 bin adet 2027, CAGR'da ilerliyor 3% tahmin dönemi boyunca, StratejiHelix'e göre.
-
Breast Cancer Market in China
StratejiHelix'e göre, the breast cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.2% itibaren 2021 başından sonuna kadar 2027.
-
Non-small-cell Lung Carcinoma (NSCLC) Çin'deki Pazar
At 3% CAGR, the non-small-cell lung carcinoma (NSCLC) market in China is projected to reach 967 bin adet 2027, veri ve analiz şirketi StratejiHelix'e göre.
-
Nasopharyngeal Cancer Market in China
According to a statistic by StrategyHelix, the nasopharyngeal cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.2% in the next five years.
-
Head and Neck Cancer Market in China
The head and neck cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.7% itibaren 2021 başından sonuna kadar 2027, veri ve analiz şirketi StratejiHelix'e göre.
-
Oncology Drug Market in China
The oncology drug market in China is poised to grow at a CAGR of around 13.3% analiz dönemi boyunca 2021 ile 2027, veri ve analiz şirketi StratejiHelix'e göre.